Skip to content
Calculator
Analysis

Enlicitide (Lipfendra): the oral macrocyclic peptide for cholesterol

Last updated: October 27, 2026 · 8 min read · By the Grey Peptides Editorial Board

Elderly female doctor using a stethoscope during a virtual consultation in a medical office
Photo by Tima Miroshnichenko on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • Enlicitide is a ring-shaped, or macrocyclic, peptide taken as a daily tablet that blocks PCSK9, the protein that drives the breakdown of the liver's LDL receptors. FDA approved it on July 15, 2026; the other PCSK9-targeting drugs are injected.
  • In phase 3 trials it lowered LDL cholesterol by about 56 to 59 percentage points more than placebo at 24 weeks, including in familial hypercholesterolaemia, and by far more than ezetimibe or bempedoic acid in a direct comparison.
  • It is approved to lower LDL, not yet to prevent heart attacks. Its outcomes trial, in 14,550 people, is not expected to finish its primary phase until late 2029.

What PCSK9 does, and why blocking it lowers cholesterol

LDL receptors on liver cells clear LDL cholesterol from the blood. PCSK9 binds those receptors and drives their breakdown; enlicitide binds PCSK9 and stops it binding the receptors, so more receptors are left to clear LDL 1 2.

Other PCSK9-targeting drugs were there first: the antibodies alirocumab and evolocumab and the small interfering RNA inclisiran 3. Lipfendra's own label notes that outcomes trials have shown fewer major cardiovascular events when LDL was lowered with statins, or with monoclonal antibody PCSK9 inhibitors added to statins 2. Merck's team describes targets like this one as historically reachable only by injected biologic drugs, and macrocyclic peptides such as enlicitide as beginning to open them to pills 4.

The macrocycle: how a peptide became a pill

Enlicitide is a macrocyclic peptide, a chain of amino acids closed into a ring and braced with chemical cross-links. Merck's chemists describe building it from four fragments around the ring, plus a tail, so they could fix one problem at a time in an earlier lead compound: a sulphur atom that oxidised, poor solubility, an explosive azide group that made manufacture hazardous, and a double bond that formed mixtures of isomers. The result bound PCSK9 at low picomolar concentrations with better solubility, stability and pharmacokinetics 5.

Making it at scale was a challenge of its own. A 2026 report in Science describes assembling enlicitide with a cascade of engineered enzymes that join peptide fragments and close the ring without protecting groups, cutting the number of synthesis steps by more than half compared with earlier methods; its authors are Merck scientists 4.

Getting it absorbed: the role of sodium caprate

Even a well-engineered peptide is poorly absorbed from the gut. Each Lipfendra tablet contains sodium caprate, a fatty-acid salt that helps enlicitide cross the intestinal wall, and even so its oral bioavailability is about 1% 2. Oral semaglutide takes the same route: its tablets are co-formulated with SNAC, which facilitates absorption 6. Icotrokinra, the oral psoriasis peptide approved in March 2026 7, is the other recent oral peptide; our icotrokinra explainer covers how it is absorbed.

Low, enhancer-dependent absorption is why the label is precise. Lipfendra is taken once daily in the morning on an empty stomach, swallowed whole with water, black coffee or plain tea, and nothing else is eaten or drunk for at least 30 minutes; taken 30 minutes after a meal, exposure fell by about half (48% for total exposure and 50% for the peak) 2. Black coffee and plain tea made no clinically meaningful difference 2. These instructions are reproduced from the label for information, not as advice.

How the dose was chosen

The phase 2b trial gave 380 people one of four daily doses or placebo for eight weeks. LDL fell by 41.2%, 55.7%, 59.1% and 60.9% against placebo on 6, 12, 18 and 30 mg, with adverse events at rates similar to placebo 8. The gains shrank at the top: going from 18 to 30 mg added under two points. The phase 3 programme then tested a single 20 mg daily dose, the dose on the label 9 2. The label also notes that blood levels rise less than proportionally with dose across a wide range 2, so a higher dose would not simply mean proportionally more drug in the blood.

What the trials showed

The trial programme, called CORALreef, tested enlicitide against placebo in a broad population and in familial hypercholesterolaemia, and against the other oral add-on drugs 8 9 10 11. Merck (MSD) sponsored the trials, and its staff are among their authors:

TrialWhoLDL cholesterol result
Phase 2b dose-finding380 treated adultsDown 41.2% to 60.9% against placebo at week 8, rising with dose
CORALreef Lipids (phase 3)2,909 adults with, or at risk of, atherosclerotic disease-57.1% vs +3.0% on placebo at week 24 (difference -55.8 points); still lower at week 52
CORALreef HeFH (phase 3)303 adults with heterozygous familial hypercholesterolaemia-58.2% vs +2.6% at week 24; -55.3% vs +8.7% at week 52
Against oral add-ons (phase 3)301 statin-treated adults-64.6% at day 56, vs -6.3% bempedoic acid, -27.8% ezetimibe, -36.5% both

The main trial enrolled 2,909 adults, average age 63 and 39% women, who had already had a heart attack, stroke or similar event with LDL of at least 55 mg/dL, or were at risk of a first event with LDL of at least 70 mg/dL; average LDL at the start was 96 mg/dL. Enlicitide also lowered non-HDL cholesterol, apolipoprotein B and lipoprotein(a), and adverse events did not appear to differ from placebo 9. A meta-analysis of the four randomised trials, 3,894 participants, put the average LDL reduction at about 56 percentage points, with reductions of about 48 points in apolipoprotein B and 23 points in lipoprotein(a) 12. Lipoprotein(a) matters because it contributes to atherosclerotic disease and no therapy is approved solely to lower it; a separate analysis of 31 trials found that the PCSK9-targeting drugs as a group lower it by about a quarter, without significant differences between them 3.

Who was studied, and who was not

The trials tell you who the evidence applies to. CORALreef Lipids enrolled adults who had already had a major atherosclerotic event, such as a heart attack or stroke, with LDL of at least 55 mg/dL, and adults at risk of a first event with LDL of at least 70 mg/dL 9. The familial hypercholesterolaemia trial enrolled 303 adults with the inherited form, on background statins and, in 64.4%, ezetimibe as well 10. The head-to-head trial compared enlicitide with ezetimibe and bempedoic acid in 301 adults already taking statins 11.

The trials enrolled adults, and the approved indication is for adults; the label says safety and effectiveness have not been established in children, and advises stopping the drug when pregnancy is recognised unless the benefits outweigh the risks 2. The phase 3 lipid trials ran for 52 weeks at most 9 10.

How it compares with injected PCSK9 drugs

We found no randomised trial comparing enlicitide directly with the injected PCSK9 antibodies or with inclisiran, so claims about which lowers LDL most rest on comparisons across separate trials with different patients. The LDL reduction in CORALreef Lipids was about 56 points against placebo 9, and the meta-analysis found a similar figure across all four trials 12. What enlicitide does not yet have, and the antibodies do, is outcomes-trial evidence of fewer major cardiovascular events 2 13.

For lipoprotein(a), the 31-trial analysis found no significant differences between the PCSK9-targeting drugs and concluded that the choice may reasonably rest on dosing frequency, cost and patient preference 3. Lipfendra is one tablet every morning on an empty stomach 2.

What the label says

FDA approved Lipfendra on July 15, 2026 as an adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia 1 2. The dose is one 20 mg tablet daily, and the label says its effect on LDL can be measured as early as four weeks after starting 2. Steady state is reached in about seven days. The drug is barely metabolised and is cleared mainly by the kidneys, about 73% of an intravenous dose appearing in urine; its effective half-life is about 14 hours, with a much longer terminal phase of about 244 hours 2. When our entry last checked the European Medicines Agency's register, on September 30, 2026, it was not listed 1.

The question still open: heart attacks and strokes

Lipfendra was approved on its LDL results 2. Enlicitide's outcomes trial, CORALreef Outcomes, has enrolled 14,550 participants at high cardiovascular risk and is active but no longer recruiting; its primary outcome is time to a first major cardiovascular event, and its estimated primary completion date is November 29, 2029 13 12. Until it reports, the claim that enlicitide prevents heart attacks rests on the class and on LDL, not on enlicitide itself. Its label says exactly that, citing outcomes trials of statins and the injected PCSK9 antibodies rather than of Lipfendra 2.

Where it fits

For people whose LDL stays too high on a statin, the other tablets are ezetimibe and bempedoic acid. In the direct comparison, in statin-treated adults over 56 days, enlicitide lowered LDL by 64.6%, against 27.8% for ezetimibe, 6.3% for bempedoic acid and 36.5% for the two together 11. The trade-offs are the strict morning routine 2 and the outcomes data still to come 13.

Merck's team presents enlicitide as an example of macrocyclic peptides opening injection-only targets to pills 4; our 2026 pipeline overview puts it and icotrokinra in context.

Frequently asked questions

What is Lipfendra?

Lipfendra is the brand name for enlicitide, a once-daily oral peptide that blocks PCSK9 to lower LDL cholesterol. FDA approved it on July 15, 2026 for adults with high LDL cholesterol, including familial hypercholesterolaemia.

How much does enlicitide lower cholesterol?

In the main phase 3 trial, LDL cholesterol fell 57.1% on enlicitide against a 3.0% rise on placebo at 24 weeks, a difference of about 56 percentage points.

Does enlicitide prevent heart attacks?

That has not yet been shown for enlicitide itself. Its outcomes trial, CORALreef Outcomes, has 14,550 participants and an estimated primary completion date of November 29, 2029.

How do you take Lipfendra?

The label says one 20 mg tablet in the morning on an empty stomach, swallowed whole with water, black coffee or plain tea, waiting at least 30 minutes before other food or drink.

Sources

  1. Grey Peptides encyclopedia entry for enlicitide: approval details (Drugs@FDA NDA 220848; EMA register read September 30, 2026) and mechanism (Lipfendra label, section 12.1). Read October 27, 2026.
  2. Merck Sharp & Dohme. Lipfendra (enlicitide decanoate) tablets, US prescribing information, sections 1, 2, 8.1, 8.4, 12.1 and 12.3 (DailyMed set 100ec543, version 2, effective July 15, 2026; confirmed current on DailyMed October 27, 2026). DailyMed
  3. Mulligan, M. D., et al. (2026). Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials. J Clin Lipidol, 20(6), 1054-1064. PMID: 42025558
  4. Klapars, A., et al. (2026). Biocatalytic cascades enable manufacture of the macrocyclic peptide enlicitide. Science, 392(6798), 643-647. PMID: 42096573
  5. Josien, H., et al. (2026). Discovery Process of Enlicitide, a Highly Engineered Macrocyclic Peptide Therapeutic, through Issue-Driven Fragment-Based Synthetic Assembly and SAR. J Med Chem, 69(11), 13473-13491. PMID: 42201324
  6. Novo Nordisk. Rybelsus (semaglutide) tablets, US prescribing information, section 12.3 (DailyMed set 27f15fac, version 14, effective January 30, 2026; confirmed current on DailyMed October 27, 2026). DailyMed
  7. US FDA. Novel Drug Approvals for 2026 (Lipfendra, July 15, 2026; Icotyde). Content current as of October 20, 2026; read October 27, 2026. FDA
  8. Ballantyne, C. M., et al. (2023). Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616. J Am Coll Cardiol, 81(16), 1553-1564. PMID: 36889610
  9. Navar, A. M., et al. (2026). A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. N Engl J Med, 394(6), 529-539. PMID: 41879224
  10. Ballantyne, C. M., et al. (2026). Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial. JAMA, 335(2), 129-139. PMID: 41206969
  11. Catapano, A. L., et al. (2026). Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial. J Am Coll Cardiol, 88(3), 340-352. PMID: 42017875
  12. Yagmur, B., et al. (2026). Enlicitide, a Novel Oral Macrocyclic Peptide PCSK9 Inhibitor for Lipid Lowering: A Systematic Review and Meta-Analysis. J Cardiovasc Dev Dis, 13(8). PMID: 42645869
  13. ClinicalTrials.gov. NCT06008756: Enlicitide decanoate (MK-0616) cardiovascular outcomes study (CORALreef Outcomes), phase 3, 14,550 participants, active not recruiting, primary completion estimated November 29, 2029. Re-read October 27, 2026. ClinicalTrials.gov

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead